Dr.
Financial Highlights
The revenue increased by 142% year-on-year from 102 million[1] for the six months ended
The research and development expenses increased from 185 million for the six months ended
The loss for the period excluding the impact of foreign exchange increased from 233 million for six months ended
The cash and cash equivalents[3] slightly decreased from 6,550 million by the end of 2021 to 6,519 million for the six months ended
By now, InnoCare has built a robust pipeline, with orelabrutinib and tafasitamab at the commercial stage, 11 clinical stage assets and five other IND enabling stage candidates. Over 30 clinical trials are ongoing in
Forward-looking Statement
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in
Contact:
Building 8, No.
Tel: +86 10 6660 9999
Fax: +86 10 6070 2992
EMAIL: IR@innocarepharma.com
(C) 2022 Electronic News Publishing, source